Stockwinners Market Radar for September 28, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

16:16 EDT Leafly names Suresh Krishnaswamy CFO - Leafly Holdings announced Suresh Krishnaswamy will join Leafly as its new Chief Financial Officer. Suresh brings more than 25 years of experience in leading finance and technology roles for global organizations, and is joining Leafly following the announcement that the Company will go public through a business combination with Merida Merger Corp. I. "As a cannabis discovery destination for more than 125 million people every year and a business platform for more than 12,400 cannabis brands and retailers combined, Leafly is a compelling marketplace that drives value throughout the cannabis ecosystem. I'm excited to bring my experience with emerging e-commerce companies to Leafly's next chapter. For a company that started as a spreadsheet a little more than a decade ago, I'm amazed at the business Leafly is today, and energized to use my expertise and leadership to take Leafly through this next phase of growth," said Suresh.

16:15 EDT Wave Life Sciences presents new ADAR editing data, update on AATD program - Wave Life Sciences announced new data for its ADAR-mediated RNA editing capability, or ADAR editing, including new preclinical editing data across multiple tissues, as well as an update on its discovery-stage alpha-1 antitrypsin deficiency, or AATD, program during the company's 2021 Analyst and Investor Research Webcast. The webcast also included updates on the company's PRISM platform and initial results from the application of ADAR editing to neurology targets. Wave's RNA editing capability leverages widely expressed endogenous ADAR enzymes to achieve highly specific A-to-I RNA editing using stereopure oligonucleotides, called "AIMers," without the need for lipid nanoparticles (LNPs) or viral vectors, and without altering the genome. Wave is developing short, fully-chemically modified AIMers with and without GalNAc conjugation, with the objective of achieving productive editing in the liver, central nervous system, or CNS, and other tissues. CNS: Wave presented new in vivo data that demonstrated potent editing and durable editing of UGP2 mRNA out to at least four months in multiple regions of the CNS in a mouse model with human ADAR. Wave is applying ADAR editing to multiple therapeutic targets in the CNS, including MECP2, seeking to correct a nonsense mutation and potentially restore functional protein in Rett Syndrome. Additionally, in vitro data were presented demonstrating the potential to target protein-protein interactions and upregulate downstream gene expression with AIMers. Ophthalmology: Wave also presented preclinical data demonstrating up to 50% editing of UGP2 mRNA in the posterior of the eye of mice at one-month post-single intravitreal injection. New tissue and cell types: Wave shared ACTB RNA editing in non-human primates using systemic administration, including in the kidneys, liver, lungs and heart, as well as editing of ACTB in multiple immune cell types in vitro, including CD4+ T-cells, CD8+ T-cells, and others. Wave's AATD program, its first investigational ADAR editing program, uses AIMers to potentially correct the single base mutation in mRNA coded by the SERPINA1 Z allele. ADAR editing may provide an ideal approach for addressing AATD by increasing circulating levels of functional alpha-1 antitrypsin protein and reducing mutant protein aggregation in the liver, thus potentially addressing both the lung and liver manifestations of the disease. Wave shared new in vivo data demonstrating durable restoration of M-AAT protein in the liver of transgenic mice with human SERPINA1 and human ADAR following initial doses of a GalNAc-conjugated SERPINA1 AIMer. Serum concentrations of human AAT protein remained at least three-fold higher over PBS control for 30 days post-last dose with the SERPINA1 AIMer. Wave also shared data demonstrating progress in enhancing editing activity and protein restoration following PRISM chemistry optimization. These AIMers achieved mean editing of approximately 50% of SERPINA1 mRNA in vivo. Also with chemistry optimization, Wave demonstrated in vivo a four-fold increase over PBS control in AAT protein restoration in serum (or more than 15 micromolar), representing an improvement over the three-fold increase achieved with Wave's initial AIMers. Approximately 85% of circulating AAT was confirmed to be M-AAT in treated transgenic mice with human SERPINA1 and human ADAR. Wave's ADAR editing appears highly specific with nominal off-target edits observed following transcriptome analysis, nor were there bystander edits observed in the SERPINA1 transcript. Ongoing and planned preclinical studies are assessing durability, dose response, pharmacokinetics, and pharmacodynamics. Wave also plans to assess reduction of Z-AAT aggregates in the liver and changes in liver pathology in its transgenic mouse model. Wave expects to have an AATD development candidate in 2022.

16:10 EDT Arcutis Biotherapeutics expands patent portfolio with roflumilast patent - Arcutis Biotherapeutics announced a new patent issued by the United States Patent and Trademark Office covering its invention for improving delivery and extending half-life of both the cream and foam formulations of topical roflumilast. Arcutis is developing topical cream and foam formulations of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor to treat psoriasis, atopic dermatitis, and seborrheic dermatitis. Clinical trial data has shown that Arcutis' topical roflumilast formulations are uniquely suited to address unmet patient needs without difficult trade-offs between efficacy, safety, and tolerability. "We believe this new patent represents important additional protection for our unique, proprietary topical roflumilast treatment, and is separate and distinct from our formulation patents. While we believe our issued and pending formulation patents provide substantial protection for topical roflumilast, having this additional patent covering the unique pharmacokinetic characteristics of our treatment is meaningful additional protection," said Frank Watanabe, Arcutis' President and Chief Executive Officer. "This new patent also further validates Arcutis' dermatological development platform that builds on our deep dermatological expertise, which includes one of the foremost topical formulators and five dermatology clinicians on staff. With eight issued patents and additional pending patents, we expect patent protection at least into 2037."

16:08 EDT JanOne to revise development strategy for trial of JAN101 - JanOne announced that it is revising its development strategy based on recent communications with the U.S. FDA for its upcoming clinical trial of lead drug candidate JAN101 as a treatment for Peripheral Artery Disease. JanOne previously submitted data from the product's Phase 1 and Phase 2a studies showing improved vascular function and a reduction in pain, which was integrated into its Phase 2b protocols and primary and secondary endpoints. The FDA reviewed the data and it provided recommendations and comments on the planned clinical trial to JanOne. Tony Giordano, Ph.D., Chief Scientific Officer of JanOne commented, "We are very happy with the thorough review of our pre-Phase 2b briefing materials from the FDA. We are working now with our partners to incorporate all the recommendations and comments provided by the FDA into our Phase 2b protocol and supporting documents and we feel that this will result in a much stronger study. Our desire is to get a drug to market as soon as reasonably possible to start treating patients with PAD and to provide them with a therapeutic benefit not available to them with current treatments."

16:06 EDT Fusion Pharmaceuticals names Mohit Rawat as President and Chief Business Officer - Fusion Pharmaceuticals announced the appointment of Mohit Rawat as President and Chief Business Officer. Rawat brings to Fusion more than 15 years of experience in the biopharmaceutical industry, with expertise in corporate strategy, business development and commercial execution, including product development, launch planning and commercialization.

16:02 EDT Carepoint Pharmacy to partner with Impel NeuroPharma to dispense Trudhesa - Carepoint Pharmacy announces that it will partner with Impel NeuroPharma to begin dispensing Trudhesa, or dihydroergotamine mesylate, nasal spray for the acute treatment of migraine with or without aura in adults. Trudhesa, approved by the FDA on September 2, uses Impel's proprietary Precision Olfactory Delivery, or POD, technology to gently deliver dihydroergotamine mesylate. Carepoint Pharmacy's digital pharmacy solutions will support people with migraine throughout the country through this partnership. Carepoint Pharmacy is only one of two digital pharmacies selected to dispense Trudhesa as part of a limited distribution network.

15:52 EDT Facebook Oversight Board agrees on removal of post on South African society - "The Oversight Board has upheld Facebook's decision to remove a post discussing South African society under its Hate Speech Community Standard. The Board found that the post contained a slur which, in the South African context, was degrading, excluding and harmful to the people it targeted. In May 2021, a Facebook user posted in English in a public group that described itself as focused on unlocking minds. The user's Facebook profile picture and banner photo each depict a black person. The post discussed "multi-racialism" in South Africa, and argued that poverty, homelessness, and landlessness have increased for black people in the country since 1994. It stated that white people hold and control the majority of the wealth, and that wealthy black people may have ownership of some companies, but not control." said the Oversight Board in a statement. Some key findings from the Oversight Board included that 'Facebook removed the content under its Hate Speech Community Standard for violating its policy prohibiting the use of slurs targeted at people based on their race, ethnicity and/or national origin. The company noted that both "k***ir" and "n***er" are on Facebook's list of prohibited slurs for the Sub-Saharan market. The Board agreed with Facebook that the content did not condemn or raise awareness of the use of "k***ir," and did not use the word in a self-referential or empowering manner. As such, no exception to the company's Hate Speech Community Standard applied in this case. The Oversight Board upholds Facebook's decision to remove the post," said the Oversight Board in part. Reference Link

14:56 EDT Xperi unit DTS says Novatek Microelectronics will be supporting DTS Play-Fi - DTS, "a firm in next-generation audio, imaging and sensing technology " and a wholly owned subsidiary of Xperi Holding announced that Novatek Microelectronics will be supporting DTS Play-Fi on its line of SoCs targeting the TV market. DTS Play-Fi adds category-leading wireless audio features to TVs including whole-home TV audio streaming, multi-room music playback from leading music services, app-based headphone streaming with Wi-Fi range, and immersive surround sound. Because Play-Fi works over industry standard Wi-Fi, no additional hardware is required in the product's design, and manufacturers can add advanced wireless capabilities across a wide range of price points within their product portfolio.

14:48 EDT Xbox Cloud Gaming beta on console begins release to insiders - Jake Rosenberg, Senior Program Manager at Microsoft's (MSFT) Xbox said in an earlier blog posting: "Play with cloud gaming on your console - no installs required. With Game Pass Ultimate, you can now play games on your console without installing. We're beginning to flight cloud gaming today on your console for a random subset of Alpha Skip-Ahead and Alpha Insiders. We will be expanding to more Insiders and additional rings over time. Cloud gaming on your console reduces your time to the fun and allows you to quickly jump into online multiplayer sessions with your friends by letting you play Xbox Game Pass games without having to wait for an install. Plus, save space on your hard drive! To get started, navigate to Xbox Game Pass on your console and look for games with the cloud icon." The Fly notes that other gaming platform makers include: Nintendo (NTDOY) and Sony (SONY). Reference Link

14:26 EDT Peloton extends decline over 3% after Amazon announces Halo Fitness - Shares of Peloton (PTON) are now down over 3% or $2.95 per share to $89.15 after Amazon (AMZN) announced expansions to Amazon Halo with three new additions to the Halo family: Halo View, a new health tracker with an AMOLED color display "for at-a-glance access to Halo health metrics; Halo Fitness, a new service with hundreds of studio-quality workout classes; and Halo Nutrition, a new experience to help build healthy eating habits. Halo View comes bundled with a full year of Halo membership for just $79.99, and will ship in time for the holidays," said Amazon.

14:01 EDT Endo reports agreement in principle to settle Louisiana governmental opioid case - Endo International announced that it has reached an agreement in principle with the Louisiana Attorney General's office to settle all opioid-related cases and claims of the state and other Louisiana governmental persons and entities in exchange for a total payment of $7.5M. The settlement, including the payment, will be subject to 100% participation by Louisiana's political subdivisions, to be provided to Endo by October 28, and the execution of definitive documentation. "The settlement will include no admission of wrongdoing, fault or liability of any kind by Endo and its value should not be extrapolated to any other opioid-related cases or claims," the company stated. As Endo has previously disclosed, the company is focused on its primary goal of achieving a global settlement of all remaining opioid claims. "At the same time, Endo is exploring other strategic alternatives and will pursue settlements that it believes are in the best interests of the Company. Endo cannot speculate on the likelihood, nature or timing of any outcome," the company said. Matthew Maletta, Executive Vice President and Chief Legal Officer of Endo, added: "The Attorney General's constructive approach provided the opportunity for accelerated negotiation and resolution, and once the required political subdivision participation threshold is achieved, funds will be promptly delivered to Louisiana to help address the state's opioid abuse crisis."

13:29 EDT Teladoc designated pre-qualified vendor by Canada Health Infoway - Teladoc Health has been designated as a pre-qualified vendor by Canada Health Infoway to provide remote patient monitoring solutions across provinces and territories serving approximately 60 percent of Canada's population. Earlier this year, Teladoc Health was also chosen as a vendor for virtual visits to improve access to healthcare for people in Canada.

13:18 EDT Hyzon Motors 'disagrees' with conclusions of short-seller report - Hyzon Motors addressed a September 28, 2021 report targeting Hyzon, published by a firm that the company believes has a short position in the company's shares. It said: "While the Company disagrees with the conclusions of the report, which it believes are based on a number of factual inaccuracies, it is reviewing the report carefully and intends to respond further in due course."

13:17 EDT Amazon announces 'Glow' interactive device for kids - Amazon announced "Amazon Glow," which it calls "a new interactive device that brings a new magic to video calls and transforms the way kids connect with remote loved ones by participating in activities together." Amazon said: "During video calls on Glow, kids see remote loved ones on a dedicated 8" display while reading stories, playing games, and creating art on a 19" touch-sensitive, projected space. At the same time, remote family and friends see the child on a tablet and participate in the same activities using the free Glow app. Glow creates a virtual experience that feels like being together in the same room." Joerg Tewes, General Manager, Amazon Glow, added: "We've created an unbreakable, supersized, projected surface like no other, fusing digital and physical fun that excites kids and delights grown-ups with all they can do together." Glow is available at an introductory, early access price of $249.99, with an MSRP of $299.99, and comes with a mat, a mat case, 1-year of Amazon Kids+, and is bundled with Tangram Bits. Glow works with a free mobile app on Android and iOS tablets, with Fire OS coming soon, Amazon said.

13:16 EDT Amazon introduces Echo Show 15 wiith 15.6-inch display - Amazon introduced Echo Show 15, a new addition to the Echo Show family "that is designed to be the digital heart of your home," the company said in a statement. It added: "With a 15.6-inch, 1080p Full HD display, Echo Show 15 can be mounted on a wall or placed on a counter-either in portrait or landscape orientation-and is designed to help you stay organized, connected, and entertained. Echo Show 15 is built with the next-generation Amazon AZ2 Neural Edge processor, a redesigned home screen with more customization options, new personalization features with visual ID, and all-new Alexa experiences." "Today, families juggle multiple competing priorities-what time to drop the kids off at soccer practice, what to make for dinner, or when to schedule the next appointment-the list goes on and on. With Echo Show 15, Alexa can help," said Tom Taylor, senior vice president, Amazon Alexa. "Echo Show 15 brings everything that makes your household tick into one place. With a redesigned home screen and Alexa widgets, you can customize Echo Show 15 to see your shared family calendar, manage to-do lists and reminders, find meal inspiration, and keep track of your incoming packages. Plus, Echo Show 15 can adapt to your home environment with full-screen photos or art, so it's always there when you need it, but fades beautifully into the background when you don't."

13:05 EDT Amerisource, Cardinal, McKesson reach pact with Cherokee Nation on opioid claims - AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) announced that they have reached an agreement with the Cherokee Nation to pay approximately $75M over 6.5 years to resolve opioid-related claims. This settlement was negotiated in connection with ongoing negotiations toward a broad resolution of opioid-related claims brought by Native American tribes that, as previously disclosed by the companies, are not covered by the ongoing settlement process involving state and local governmental entities. The companies view today's settlement as an important step toward reaching a broader settlement with all federally recognized Native American tribes across the country. This settlement reflects an agreement of the Cherokee Nation to dismiss its ongoing lawsuit in exchange for the companies' agreement that the Cherokee Nation will receive a settlement amount consistent with its anticipated allocation under a broader agreement with Native American tribes. While the companies strongly dispute the allegations against them, they believe this resolution will allow the companies to focus their attention and resources on the safe and secure delivery of medications and therapies while delivering meaningful relief to affected communities, and will also support efforts to achieve a broad resolution with the remaining Native American tribes.

12:59 EDT Amazon partners with Disney on Alexa voice assistant features - Amazon (AMZN) announced in a device unveiling event, and associated blog, that it is introducing an Alexa Custom Assistant in partnership with Disney (DIS). Amazon said: "'Hey, Disney!' is an entirely new kind of voice assistant developed by Disney and built on Amazon's Alexa technology. Whether you are at home or in a Walt Disney World Resort hotel, you will soon be able to use a supported Echo device to interact with beloved characters from Disney, Pixar, Marvel, Star Wars, and beyond. 'Hey, Disney!' and the Disney Magical Companion were developed from the ground up by our friends at Disney, using Alexa Custom Assistant. This made it easy for Disney to create their own custom voice assistant, built on Alexa technology. The 'Hey, Disney' voice assistant features a unique wake word, voice, personality, and capabilities." In addition, Amazon announced the upcoming availability of the new Mickey Mouse-inspired stand for Echo Show 5 from Otterbox.

12:55 EDT Corning announces expansion of collaboration with AT&T - Corning Incorporated (GLW) announced it is expanding its longtime collaboration with AT&T (T). The two companies will work together to extend investments in fiber infrastructure, expand U.S. broadband networks, and accelerate 5G deployment, Corning said in a statement. Based on AT&T's long-term commitment to its network buildout, Corning is investing $150M in optical cable manufacturing in North Carolina, initially adding 200 jobs, it added. AT&T has previously announced plans to significantly expand its fiber footprint. "We see expansion of our fiber infrastructure as central to the growth of our broadband reach, for consumers as well as business customers," said Mo Katibeh, senior vice president, AT&T Network Infrastructure & Build. "By extending our collaboration with Corning, we'll create American jobs through manufacturing investments, and also through the economic benefits that broadband brings to our communities."

12:42 EDT Teva settles Louisiana opioid-related claims for $15M over 18 years - Teva Pharmaceutical said it has reached an agreement with the Attorney General of Louisiana that settles the state's opioid-related claims. The agreement is contingent on confirmation from the state by November 2, that all political subdivisions will release Teva as part of the settlement. Under the terms of the settlement, Teva will pay Louisiana $15M over an 18-year time period and will provide an additional donation of lifesaving medicines to aid in opioid addiction and recovery, valued at $3M. Teva "continues to negotiate a national settlement and remains open in parallel to pursuing opportunities with individual states such as the deal announced today, as long as it is consistent with the nationwide approach. The Company will continue to defend itself in court in states such as New York and California where we have not reached terms of a settlement agreement," the company said in a statement.

12:00 EDT MoneyLion falls -9.8% - MoneyLion is down -9.8%, or -86c to $7.89.

12:00 EDT Direxion Daily Semiconductor Bull 3X Shares falls -10.5% - Direxion Daily Semiconductor Bull 3X Shares is down -10.5%, or -$5.03 to $42.66.

12:00 EDT TEN, Ltd. rises 13.7% - TEN, Ltd. is up 13.7%, or $1.24 to $10.26.

11:59 EDT Curo Group sees FY21 Canada revenue C$735M vs. previous C$643M view - Management raised 2021, 2022 and 2023 Canadian revenue targets to C$364M from C$342M, C$550M from C$480M, and C$735 million from C$643M, respectively.

11:46 EDT Nintendo says Donkey Kong expansion to Super Nintendo World to open in 2024 - Nintendo (NTDOY) announced an expansion to its Super Nintendo World theme park at Universal Studios Japan (CMCSA) that will be theme after Donkey Kong. The area will feature a roller coaster, interactive experiences and themed merchandise and food. "Guests will be able to take a walk on the wild side through the lush jungles where Donkey Kong and his friends live," Nintendo said. The new area is set to open in 2024.

11:34 EDT DoubleVerify partners with TikTok to measure viewability, invalid traffic - DoubleVerify announced a partnership with TikTok to measure ad viewability, fraud, and in-geo impressions. Through this new partnership, joint clients will be able to access measurement data and insights through DV Pinnacle, a unified reporting and service platform, to monitor and optimize the quality of their TikTok campaigns. "We're excited to work with a leading verification and industry authority partner, like DoubleVerify" said Melissa Yang, Head of Ecosystem Partnerships, TikTok. "Transparency is key when it comes to building strong relationships with brands. Partnering with DoubleVerify will allow our advertisers the in-depth insight they need on invalid traffic and viewability to confidently evaluate and validate campaign effectiveness on TikTok." DoubleVerify and TikTok are actively working to expand their viewability offering to other ad formats and will launch additional media quality solutions - providing comprehensive measurement across the platform.

11:26 EDT Shopify, Square among third-party commerce partners for TikTok Shopping - TikTok announced its "TikTok World" event, which it calls a "global experience designed to help brands and marketers embrace the TikTok experience and reimagine how they connect with their communities" and offered highlights from TikTok World in a blog post. In its blog post, TikTok stated in part: "We're excited to introduce TikTok Shopping, a suite of solutions, features, and advertising tools that empowers brands and merchants to meaningfully engage with their customers... Merchants can tap into a full commerce experience with the capability to upload products and manage everything from shipping to fulfillment and point of purchase... For merchants who enjoy working with their preferred third-party commerce partner, we're excited to have Shopify (SHOP), Square (SQ), Ecwid, PrestaShop now available on the platform. We expect Wix (WIX), SHOPLINE, OpenCart, and BASE to be available soon... The TikTok community is reshaping the way we discover new products and shop. When creators feel passionate about a product or brand, they share it in an authentic way that resonates with the community. We strive to bring more commerce solutions to TikTok that further enable our community to discover and engage with what they love." Reference Link

11:10 EDT Hain Celestial actively pursuing M&A transactions, company says at Investor Day

11:04 EDT Amazon Games announces launch of 'New World' on PC - Amazon Games announced it has launched "New World" on PC. "New World is a massively multiplayer online role-playing game that pits players against the haunted wilderness of Aeternum, a mysterious supernatural island in the twilight of the Age of Exploration," the company stated. New World is available on Amazon.com and Steam. The Standard Edition is $39.99, and the Deluxe Edition, featuring the Woodsman armor and hatchet skins, Mastiff house pet, Rock/Paper/Scissors emote set, and New World digital art book, is available for $49.99.

10:47 EDT AIkido Pharma secures equity interest in electric truck producer Tevva Motors - AIkido Pharma announced that the company secured an equity interest in Tevva Motors Ltd, an electric truck producer with range extended vehicles on the road now. Anthony Hayes, CEO of AIkido, noted, "From a commercial standpoint, delivery trucks are a $100B global market and demand for a cost effective, zero emission solution is growing by the day. With strategic partners and early customers including, Ryder, Hitachi and UPS, and with Tevva vehicles already being used in their delivery services, Tevva is well positioned to take advantage of this rapidly growing sector."

10:40 EDT Hain Celestial jumps 1% to $40.04 as company provides update at Investor Day

10:34 EDT Ryan Seacrest signs contract with iHeartMedia to continue through 2025 - iHeartMedia announced that it has signed a new contract with Ryan Seacrest. The three-year contract extends through December 31, 2025, during which time Seacrest will celebrate 30 years as one of the most recognized and respected throughout the entire media and entertainment industry.

10:30 EDT SunLink Health says availability, cost of labor hurting Healthcare businesses - SunLink Healthy Systems stated: "In our Healthcare businesses, we have experienced material reductions in demand and net revenues due to the COVID-19 outbreak. A reduction in the availability of qualified employees has also occurred and despite good faith efforts to do so, we have not yet been able to rehire or fully replace staff reductions which were previously furloughed, laid off or retired. There appears to be minimal current demand for extended care and rehabilitation center admissions and clinic visits, and hospital services have substantially decreased, all as a result of the effects of the pandemic. The availability and cost of labor and medical supplies have adversely affected our Healthcare businesses, especially with respect to access to personal protective equipment, cleaning supplies and COVID-19 testing materials. We continue to monitor supplies and seek additional sources of many supply items. Since the beginning of the COVID-19 pandemic, our Pharmacy business has experienced reduced sales trends in certain areas, increased costs and reduced staff. Many of our primary physician referral sources have been operating at substantially reduced capacity. Until these referral sources are able to return to full capacity, we believe the COVID-19 pandemic will continue to affect the demand for DME products and Retail and Institutional Pharmacy drugs and products. Reductions in employee hours have been made in response to the lower demand. Extended care and rehabilitation centers and other customers of such Institutional Pharmacy services are currently being adversely affected by the spreading of the COVID-19 pandemic, and this may be expected to have a further negative effect on such demand. Our Institutional Pharmacy services have experienced increased costs and operational inefficiencies due to measures taken to protect our employees and by access controls and other restrictions implemented by our institutional customers. We believe the effect of the COVID-19 pandemic and public and governmental responses to it negatively affected our last six fiscal quarters results but the adverse effect of such responses was offset in such quarters by financial assistance provided by programs enacted by the CARES Act."

10:01 EDT Bahrain Electricity & Water Authority signs $28.7M contract with GE Digital - GE Digital announced that the Bahrain Electricity & Water Authority had signed a contract worth $28.7M for software and services to modernize the Kingdom of Bahrain's electricity and water networks. A variety of GE Digital's Grid Software will be installed in a state-of-the-art control center that will digitize operations for increased efficiency and operations redundancy, the company said in a statement.

10:00 EDT Kirkland Lake Gold falls -8.8% - Kirkland Lake Gold is down -8.8%, or -$3.87 to $40.03.

10:00 EDT Thor Industries rises 8.9% - Thor Industries is up 8.9%, or $10.06 to $122.86.

10:00 EDT TEN, Ltd. rises 15.0% - TEN, Ltd. is up 15.0%, or $1.35 to $10.38.

09:47 EDT Brookdale Senior Living falls -8.3% - Brookdale Senior Living is down -8.3%, or -51c to $5.63.

09:47 EDT Kirkland Lake Gold falls -10.0% - Kirkland Lake Gold is down -10.0%, or -$4.37 to $39.53.

09:47 EDT TEN, Ltd. rises 7.3% - TEN, Ltd. is up 7.3%, or 66c to $9.68.

09:42 EDT Corbus Pharmaceuticals names Craig Millian as COO - In a regulatory filing, Corbus Pharmaceuticals said that on September 24, its board appointed Craig Millian as COO. Craig Millian served as the company's Chief Commercial Officer since February 2019, and vacated such office upon appointment as COO, the company said.

09:38 EDT Spire Global, SpaceChain partner on feasibility of blockchain in space - Spire Global announced a new partnership with SpaceChain, a global space-as-a-service solutions provider developing the world's first decentralized satellite infrastructure. Together, Spire and SpaceChain are launching a mission to demonstrate the feasibility of blockchain technology computation in space and resolve land-based centralized infrastructure issues. Many in the blockchain industry have been working to reduce points of risk whereby a centralized administrator or authority can tamper with, or in the worst case, steal funds and data. One potential solution is to decentralize access by distributing data across multiple centers, countries, and continents. By deploying a solution in space, Spire and SpaceChain aim to maximize data security and increase the resiliency of computing operations. SpaceChain is reimagining the space industry, having worked with all quarters of the ecosystem ranging from launch service providers, national space agencies, satellite manufacturers to data analytics startups. The integration of blockchain and space technologies helps create a Decentralized Satellite Infrastructure on which Decentralized Satellite Applications can be built and run without the need for any land-based infrastructure. Spire will utilize its "SABERTOOTH" supercomputing module to fulfill a two-part mission with SpaceChain. Initially, Spire will conduct an on-orbit upload of SpaceChain's software to an existing satellite, before further building out SpaceChain's capabilities via a payload on a new satellite, expected to be launched later this year.

09:22 EDT AIM ImmunoTech submits Pre-IND application for Phase 2 studies of Ampligen - AIM ImmunoTech announced that is has submitted a Pre-Investigational New Drug application to the U.S. Food and Drug Administration (FDA) for two separate Phase 2 clinical studies to study the potential of Ampligen as both an infusion and an intranasal therapy for early-onset COVID-19, the disease caused by SARS-CoV-2.The two clinical trials will be Phase 2, randomized, double-blind, placebo-controlled studies to evaluate the efficacy and safety of Ampligen as an: Intravenous therapy - 200 mg of Ampligen or placebo, with five doses over a treatment period of 17 days; and an Intranasal therapy - 1,250 undefined spray, with seven doses over a treatment period of 15 days. In addition to studying efficacy and safety, the new Phase 2 protocols include exploratory endpoints that the company believes could support its recently filed provisional patent application. AIM believes that it is critical to test the potential of Ampligen as both an intravenous and an intranasal therapy for early-onset COVID-19, as there is science to support the potential of both approaches. Ampligen has demonstrated clear activity in prior SARS-CoV-1 virus animal experiments. With a SARS-CoV-1 virus mouse models, Ampligen demonstrated 100% protective survival benefit compared to 100% mortality in a saline control group. Ampligen also reduced SARS-CoV-1 lung titers to below the level of detection. Based on the SARS-CoV-1 data, AIM pursued a successful in vitro testing model at the Institute for Antiviral Research at Utah State University, with results showing that Ampligen was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels. Additionally, in June 2021 AIM announced that all subjects have completed treatment in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy. A total of 40 healthy subjects received either Ampligen or a placebo in the trial, with the Ampligen given at four escalating dosages across four cohorts, to a maximum level of 1,250 micrograms. The study reported no Severe Adverse Events at any dosage level. Intranasal Ampligen conferred a boost to homologous reactivity when used as an influenza vaccine adjuvant. Further, the TLR-3 agonist - when administered intranasally - induced epitope spreading and clear cross-reactivity against heterologous viral variant.

09:20 EDT BioSig Technologies selects Plexus as manufacturing partner - BioSig Technologies (BSGM) announced that the Company entered into a manufacturing and professional services agreement with Plexus (PLXS). Under the terms of the newly reached agreement, Plexus will bring to market the PURE EP System, the Company's signal processing technology for arrhythmia care, and develop a new product pipeline for BioSig's subsidiary NeuroClear Technologies. "We are fundamentally proud to partner with Plexus on our mission to advance therapies through technological innovation. Their engineering and manufacturing capabilities and outstanding expertise in building complex medical devices make Plexus a foundational cornerstone to support BioSig's growth objectives now and well into the future. The recent release of our clinical data has increased physician interest in our technology. We believe that the post-pandemic recovery in elective procedures will further drive our installation footprint, and we are confident that Plexus' first-class operational infrastructure will ensure a quality supply of the PURE EP systems to meet growing market needs," commented Kenneth Londoner, Chairman, and CEO of BioSig Technologies, Inc. The PURE EP is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. The Company recently completed its first multi-centered, prospective clinical trial and presented preliminary clinical data during the annual Heart Rhythm 2021 convention in July in Boston, MA.

09:19 EDT INNOVATE's R2 Technologies' Glacial Rx System earns third FDA indication - INNOVATE announced that Glacial Rx, the revolutionary in-office system from subsidiary R2 Technologies which is FDA-cleared to remove benign lesions and temporarily reduce pain, swelling and inflammation, is now the only Class II dermal cooling system FDA-cleared for general dermabrasion, scar and acne scar revision, and tattoo removal, permanently changing the aesthetics industry. "R2's pipeline of groundbreaking, first-in-class products establishes R2 as a bellwether company in the skincare industry, and we look forward to continuing to support their growth as we drive meaningful value for our stakeholders," said Wayne Barr, CEO and President of INNOVATE.

09:17 EDT MGM Japan and Orix joint venture selected by Osaka as integrated resort partner - MGM Resorts International announced that MGM Japan, together with its joint-venture partner ORIX, has been selected by Osaka as the region's integrated resort partner. Osaka's selection of the MGM-ORIX consortium marks an important step in MGM's long-term bid to develop one of Japan's first integrated resorts. Details of the proposed approximately $10B development were also unveiled, showcasing MGM's vision to bring a world-class resort experience to Osaka that is designed to transform the region into one of the world's top entertainment and hospitality destinations and that will serve as a hub for tourism across Japan. Osaka's selection of MGM-ORIX is one of several steps in the licensing process following the 2018 passage of Japan's Integrated Resort Implementation Act. The next step is for MGM, together with Osaka prefecture/city and ORIX, to submit an Area Development Plan to Japan's central government during the October 2021 to April 2022 application period. Integrated resort licenses are expected to be issued by the central government in 2022. If selected to receive a license, MGM anticipates an opening date in the second half of the 2020s for the Osaka project.

09:16 EDT BAE Systems awarded $872M Army contract - The U.S. Army has awarded BAE Systems, Inc. an indefinite delivery/indefinite quantity contract to provide life-cycle sustainment and technical support to the Limited Interim Missile Warning System program. The 10-year contract has a ceiling value of $872M.

09:15 EDT Anghami appoints Mary Ghobrial as chief operating, strategy officer - Anghami announced the appointment of Mary Ghobrial, Ex-Amazon Director Marketplace Expansion & Ex-CCO of SOUQ.com, to be the Company's new Chief Operating and Strategy Officer. Ghobrial has over twenty-five years' experience in building brands from source to leading positions. Throughout her career, Ghobrial has developed many new products within various sectors including fast-moving consumer goods, entertainment and online shopping.

09:13 EDT Telus launches Reconciliation Commitment - The company said, "TELUS has a longstanding commitment to strengthening relationships with Indigenous Peoples, including First Nations, Metis, and Inuit communities, acknowledging that our work spans many Traditional Territories and Treaty areas. Today, we are proudly launching our Reconciliation Commitment, a defining point in our journey that formalizes our commitment to Reconciliation with Indigenous Peoples. This commitment will act as the foundation upon which we develop and implement our inaugural Indigenous Reconciliation Action Plan later this year, and will inform and direct our corporate initiatives related to Reconciliation moving forward."

09:11 EDT Immediate Media renews recommendation partnership with Outbrain - Outbrain has renewed its partnership with Immediate Media and will begin utilising Outbrain's Smartfeed technology. Since 2014, Immediate Media has successfully partnered with Outbrain to drive reader engagement and boost revenue across a diverse set of publications such as BBC Good Food, Radio Times, Olive Magazine, Gardeners World, and BikeRadar. With this renewed partnership, Immediate Media will start leveraging Outbrain's Smartfeed, a customisable feed of content discovery that allows publishers to optimise the user experience to improve engagement and revenue. Smartfeed is a blank canvas on which a suite of card formats can be used to deliver editorial, monetisation, and specific revenue goals, generating a 20% RPM lift when compared to Outbrain's standard widgets.

09:09 EDT Alphatec expects Q3 spine revenue to grow 25% - Alphatec provided a business update ahead of investor meetings scheduled for the NASS 2021 meeting. The resurgence of COVID-19 in the U.S. has pressured surgical procedure volumes in spine and affected hospital operations in the third quarter of 2021, with the impact persisting into the final month of the period. While procedure volume is recovering in some regions, overall, it has been lower than expected. Despite these impacts, ATEC expects U.S. spine revenue to grow over 25% year-over-year in the third quarter due to the continued strength of surgeon adoption and increasing sales force penetration; however, the company now expects third quarter U.S. spine revenue to be down sequentially compared to the second quarter 2021. The integration of EOS imaging continues to be on track.

09:07 EDT Sabre expands partnership with Shiji Distribution Solutions - Sabre announced an enhanced partnership with Shiji Distribution Solutions to better connect hoteliers to the lucrative, yet complex, Chinese travel ecosystem. While the Chinese travel market is one of the biggest in the world, Chinese travelers have traditionally been hard to reach for many hoteliers. This expanded relationship between Sabre and Shiji will open up further access for hoteliers, through the Sabre SynXis hospitality platform, to the channels Chinese travelers typically use to search and book their trips across corporate and leisure segments. Sabre has previously worked with Shiji to connect hoteliers to selected channels within China including the popular WeChat Booking Engine, as well as Fliggy and Meituan's travel platforms. The two global technology companies have now reached a much broader agreement to enable Sabre hotel partners to quickly connect to a wider range of travel agents, online travel agencies, travel management companies and wholesalers across the Chinese marketplace.

09:06 EDT Casey's General Stores in pact to acquire 40 Pilot stores for $220M - Casey's General Stores announced an agreement to acquire 40 Pilot convenience stores from Pilot Corporation in an all-cash transaction for $220M. "Casey's is a great convenience store chain that shares similar values as Pilot and we couldn't be more excited for what they will bring to the community," said Pilot Company Chairman Jimmy Haslam. "We are very thankful for the tremendous service our team members have provided and know they will be in great hands with Casey's. Pilot and the Haslam family will always be committed to the Knoxville community, our philanthropic efforts and being a top employer in the region. The company will continue our intense focus on growing our core travel center network and energy businesses with significant investments in our people and our stores to provide the best team member and guest experience at our more than 800 locations across North America." Casey's will fund the transaction with a combination of cash on hand and bank financing. The transaction is subject to customary closing conditions and regulatory approvals, including Hart-Scott-Rodino clearance.

09:05 EDT ZoomInfo to expand global headquarters in Vancouver - ZoomInfo announced that it has signed a lease to expand its global headquarters in Vancouver, Washington. Currently located at 805 Broadway St. in downtown Vancouver, ZoomInfo will move into a four-story office at Terminal 1 along the Columbia River in 2025. ZoomInfo signed a lease for the entire building and will occupy it in a multi-phased approach.

09:03 EDT Euronet to license REN payments platform to Marker Trax - Euronet Worldwide announced it will license its REN payments platform to Marker Trax, LLC, of Las Vegas for use in the company's cloud environment where it will provide transaction processing and other core functionalities for a ground-breaking digital casino marker management system.

09:02 EDT Summit State Bank declares 10% stock dividend - Summit State Bank announced that its Board of Directors declared a 10% stock dividend to be paid on or about November 4, 2021 to shareholders of record as of the close of business on October 29, 2021. Each shareholder of the Bank will receive one additional share of stock for every ten shares owned on the record date of October 29, 2021. Cash will be paid in lieu of fractional shares based on the closing price of the common stock on the record date.

09:01 EDT United Airlines, Airlink announce new codeshare agreement - Airlines and Airlink, a South African airline, announced a new codeshare agreement that will offer customers more connections between the U.S. and Southern Africa than any other airline alliance. The new agreement, which is subject to government approval, will offer one stop connections from the U.S. to more than 40 destinations in Southern Africa. Additionally, United will be the first airline to connect its loyalty program with Airlink, allowing MileagePlus members to earn and redeem miles when they travel on Airlink flights. This new cooperation will be in addition to United's existing partnership with Star Alliance member South African Airways.

08:50 EDT Gulf Island Fabrication recommences operations following Hurricane Ida - Gulf Island Fabrication provided an update on the status of operations at its Houma, Louisiana facilities. On August 29, 2021, Hurricane Ida made landfall near Gulf Island's Houma, Louisiana facilities as a powerful Category 4 hurricane, causing significant damage to the surrounding area and leaving nearly one million residents and thousands of businesses without power and water, including the Company's Houma facilities. In an effort to return the Company to normal operations as quickly and as safely as possible, cleanup and restoration efforts commenced immediately following the passage of the storm. Power and water to the Company's facilities have been recently restored and the Company has recommenced operations. The Company does not expect the recent events to adversely impact its ability to complete projects in backlog or its ability to pursue future project opportunities. The Company is continuing to work with its insurance providers to assess the full extent of the damage to its buildings and equipment, and although the timing and amount of any insurance recovery is uncertain, the Company currently does not expect a material impact to its overall liquidity.

08:47 EDT TopBuild announces senior notes offering - TopBuild announced a private offering of $500.0 million aggregate principal amount of senior notes due 2032 to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933 and to certain non-U.S. persons in offshore transactions in accordance with Regulation S under the Securities Act. TopBuild intends to use the net proceeds from the sale of the notes, together with borrowings under a new term loan and cash on hand, to fund the purchase price payable in connection with the consummation of its previously announced acquisition of Distribution International, including the payment of related fees and expenses. The closing of the notes offering is expected to occur prior to, and is not conditioned upon, the consummation of the Acquisition. However, the notes will be subject to a "special mandatory redemption" in the event that the Acquisition is not consummated on or prior to August 7, 2022 or prior to August 7, 2022, the merger agreement is terminated, other than in connection with the consummation of the Acquisition, and is not otherwise amended or replaced. The notes will be guaranteed, on an unsecured senior basis, by all of TopBuild's subsidiaries, including DI and its affiliates that are required to become guarantors under the Company's credit agreement by its terms upon consummation of the Acquisition. The notes offering is subject to market and other conditions, and there is no assurance that the offering will be completed or, if completed, as to the terms on which it will be completed.

08:44 EDT Taboola to share its strategy on e-commerce following Connexity acquisition - Taboola is sharing with the investment community their strategy to bring more e-commerce solutions to open web publishers and more commerce value to advertisers following their acquisition of Connexity. Taboola closed its acquisition of Connexity on September 1, 2021, bringing Connexity's 6,000 publishers and 1,600 direct merchant relationships to Taboola. "We estimate that a third of our own revenue, as well as publishers in the open web will come from e-commerce over time. Especially on the back of a pandemic, people are buying online - and it's better to buy from a trusted, editorial publisher. Following the acquisition of Connexity we are uniquely positioned to offer an e-commerce strategy to our 9,000 publishers around the world, and help merchants diversify outside of walled gardens. Today is a new beginning for Taboola and our partners. We could not be more excited," said Adam Singolda, Founder & CEO, Taboola. "e-commerce will supercharge our business and position us to capture more of the $100B+ of available TAM. With Connexity, in 2022 we will be more than double what we were in 2019 in terms of ex-TAC Gross Profit and we project $100 million in annual ex-TAC gross profit synergies within four years - roughly equivalent to adding another Connexity. We are laser focused on execution and delivering on the huge opportunity before us." Key points include: the e-commerce industry is rapidly accelerating; publishers are prioritizing e-commerce to thrive; Connexity's deep e-commerce expertise amplifies Taboola revenue performance, the company said.

08:41 EDT Real Brands completes SEC Form 10 review - Real Brands has received a "No further comments" letter from the Securities Exchange Commission on its Form 10 filing as its final step prior to filing an application to uplist to the OTCQB as a fully compliant reporting publicly traded company. As part of the compliance and reporting process, Real Brands completed two years of audited financial records, appointed outside independent directors to its Board of Directors, and created an audit committee composed of three independent directors.

08:40 EDT Astronics announces $19M follow-on order from Collins Aerospace - Astronics announced it was awarded a $19M order from Collins Aerospace for business jet connectivity equipment to be delivered in 2022. The order is a follow-on to the approximately $11M order announced in February.

08:38 EDT U.S. Dept. of Labor awards Verizon Public Sector $887M in EIS task orders - The U.S. Department of Labor has awarded Verizon Public Sector five Enterprise Infrastructure Solutions task orders to modernize legacy network infrastructure including data, voice, unified communications, video services and enterprise applications for its 20,000 users. Verizon Public Sector's partnership with the DOL will result in a highly secure, converged data and voice network across nearly 1,000 locations. Verizon will partner with the DOL to drive the adoption of innovative technologies with a custom managed services solution that will support enterprise connectivity. The first task order will transform and modernize the DOL's IT backbone with new network architecture design to build a managed network with data, voice and toll-free services. The second task order will continue existing work to transform the DOL's audio and web conferencing services through a number of customized use and flexibility options. The third task order allows for the immediate delivery of Content Delivery Network Services. Verizon Public Sector will evolve these services to provide improved capabilities, creating an enterprise-level cloud environment as the foundation for implementing Infrastructure as a Service, Platform as a Service, and Software as a Service. The fourth task order will address DOL's Managed Trusted Internet Protocol Service, and calls for the installation of MTIPS ports for the DOL's seven data centers across the country. The fifth task order will support the deployment of Unified Communications Services to accommodate all 20,000 DOL end-users. The UCS will integrate multiple methods of communication, including moving to IP-based voice and video services that will enable the DOL workforce to connect, collaborate and exchange information wirelessly and seamlessly. Finally, through a task order previously issued under another solicitation, Verizon Public Sector has successfully transitioned DOL's Co-located Hosting Service (CHS) requirements from its previous GSA's Networx contract to the EIS contract vehicle. This will help reduce DOL's IT infrastructure and management costs and provide access to a data center environment that is scalable to the department's changing needs.

08:36 EDT Humanigen plans submission of MAA for CMA in EU to treat Covid pneumonia - Humanigen announced the European Medicines Agency, EMA, has appointed a rapporteur and a co-rapporteur as part of the pre-submission process related to Humanigen's plan to submit an MAA for the use of lenzilumab to treat patients hospitalized with COVID-19. These appointments by the Committee for Medicinal Products for Human Use, CHMP, are an important step in the pre-submission process leading up to the submission of the MAA. Humanigen plans to request accelerated assessment of the MAA as part of the pre-submission process. "Highlighting the ongoing need globally for therapeutics to treat patients hospitalized with COVID-19, in the EU in the most recent week for which data is available, there were 7,664 new hospitalizations and 4,429 deaths reported for COVID-19," said Cameron, Durrant, MD, Chief Executive Officer, Humanigen.1 "We remain committed to bringing lenzilumab to hospitalized patients with COVID-19 and as part of this effort, we plan to submit our MAA to the EMA as soon as possible." EU legislation allows for accelerated assessment of an MAA, reducing review time from 210 days to 150 days not counting clock stops for applicants to provide additional information, if CHMP determines a product is a major public health interest; however, this decision has no impact on the eventual CHMP opinion on whether a marketing authorization should be granted.

08:34 EDT Cardlytics appoints Chris Suh to board of directors - Cardlytics (CDLX) announced the appointment of Chris Suh, corporate vice president and CFO, Cloud+ AI Group at Microsoft (MSFT), to its Board of Directors and Audit Committee.

08:33 EDT Genasys to sponsor, exhibit at EENA Conference 2021 - Genasys announced it is a gold sponsor of the EENA Conference 2021, a three-day event and exhibition for public safety professionals to be held in Riga, Latvia, October 6 - 8, 2021. Genasys' EU Strategic Marketing Director, Pablo Gomez, is scheduled to participate in the Public Warning Solutions panel discussion at 9 a.m. EEST on October 7, 2021. The panel's focus will be solutions available on the market.

08:32 EDT IsoRay announces recognition of Cesium-131 in ABS consensus paper - The American Brachytherapy Society has recognized Isoray's Cesium-131 in its recently released new consensus statement on the subject of low dose rate prostate brachytherapy. This marks the first time Cesium-131 has been included in ABS's highly respected consensus guidelines. Because Cesium-131 seeds were not available as a treatment until 2004, long-term outcomes following Cesium-131 prostate brachytherapy seeds have only recently been available. ABS does not rank or endorse any specific treatment option, but rather is focused on evaluating evidence and providing insight into research surrounding the use of brachytherapy in addressing malignant and benign conditions. Reacting to the newly published, evidence-based consensus statement, Isoray CEO Lori Woods noted the importance of the milestone. Woods said, "We are honored that this prestigious organization has included Isoray's Cesium-131 in these consensus guidelines. It is another important step forward as we continue to innovate and build on our position as a leader in prostate brachytherapy." Entitled, Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement, the findings are a "guideline intended to present evidence-based consensus recommendations for low dose rate permanent seed brachytherapy for the treatment of prostate cancer." The paper was the result of work by an ABS convened task force. According to the ABS task force, the results of their comprehensive literature study resulted in their stating that LDR prostate brachytherapy monotherapy is an appropriate treatment option for low risk and favorable intermediate risk disease. In combination with external beam radiation, it also found LDR brachytherapy is appropriate for unfavorable intermediate risk and high-risk prostate cancer treatment. Cesium-131 has the shortest half-life and highest energy level of the radioisotopes that ABS currently recommends for LDR brachytherapy for the treatment of prostate cancer. Cesium-131's energy is powerful, allowing it to aggressively attack the cancer being treated. Its shorter half-life means the radiation delivers its treatment dose faster, reducing other issues for the patient that can come from prolonged radiation exposure. The rapid resolution of side effects is an important advantage for patients, allowing them to return to their normal lives quickly.

08:30 EDT HealthEquity announces proposed offering of $500M senior notes - HealthEquity announced that it has commenced, subject to market and other conditions, an offering of $500 million aggregate principal amount of its senior notes due 2029. It is expected that the senior notes will be guaranteed by certain of HealthEquity's subsidiaries on a senior unsecured basis. HealthEquity intends to use the net proceeds from the offering, together with cash on hand and borrowings under new credit facilities, to refinance outstanding amounts under its existing term loan and/or for general corporate purposes.

08:29 EDT Cathie Wood's ARK Investment bought 77K shares of Coinbase on Monday

08:28 EDT Cathie Wood's ARK Investment bought 299K shares of Robinhood on Monday

08:26 EDT MasterCard enters 'Buy Now, Pay Later' program Mastercard Installments - Mastercard unveiled Mastercard Installments, a Buy Now, Pay Later program. Mastercard Installments enables consumers to digitally access BNPL offers, either pre-approved through their lender's mobile banking app or through instant approval during checkout. Pre-approved installments can be used directly on a merchant's website, and can be stored in digital wallets including Click-to-Pay, to then be used online or in-store wherever Mastercard is accepted. "At the heart of it, payments come down to choice - and people want more from their money with greater flexibility and control in how they pay and where they shop," said Craig Vosburg, Chief Product Officer, Mastercard. "Mastercard Installments has been built on our guiding principles to protect consumers and enable choice without sacrificing trust and security. It is a digital-focused way to pay today and tomorrow, delivered through consumer's most trusted relationships with their banks and other lenders, at merchants of their choice."

08:24 EDT Genetic Technologies enters collaboration with Institute of Public Health - Genetic Technologies announced that they have entered into a strategic collaboration with the Institute of Public Health in St Louis USA for the purpose of expanding the predictive capabilities of the GeneType for Breast Cancer product to include women of African descent. Genetic Technologies have committed to fully fund a collaborative study with Professor Graham Colditz, Deputy Director of the Institute for Public Health. The purpose of the study is to incorporate further research and data on women of African descent to provide expanded testing capabilities for the GeneType for Breast Cancer product. There exists a significant unmet need for polygenic risk testing for ethnically diverse populations where risks of mortality from Breast Cancer is estimated to be 40% higher in African American women than Caucasian women. Polygenic risk models are required to be validated for use with multiple ethnicities and therefore GENE will be validating samples which have both genotype information and the relevant clinical information to cover this expanded population. This investment will be self-funded by GENE with costs partially offset by an R&D tax rebate estimated to be 43.5% of the costs associated with the study which is expected to contribute ~1,000 samples. The collaboration is anticipated to require around 9 months of research and processing at GTG's Melbourne Laboratory. Commenting on the study, CEO Simon Morriss stated: "Expanding our capabilities to include those of African descent is a critical element of our long-term strategy. To fully address the growing burden of common complex diseases on our healthcare systems we need to be able to provide predictive risk tests for all individuals to empower them with the information to proactively manage their health and understand their risk. This is the first step in our response to address the unmet demand for tests that have been validated on multi population datasets. We will continue to assess our product portfolio to ensure we are expanding our addressable population and providing inclusive polygenic risk scores for multi-ethnic populations."

08:19 EDT First Wave BioPharma begins patient screening for Phase 2b trial of niclosamide - First Wave BioPharma announced that it has begun screening patients for enrollment in a Phase 2b clinical trial investigating a topical formulation of FW-UP as a potential treatment for ulcerative proctitis and ulcerative proctosigmoiditis. FW-UP is a proprietary topical formulation of niclosamide, a small molecule anti-inflammatory inhibitor therapy. UP and UPS are two types of ulcerative colitis, a chronic inflammatory bowel disease consisting of fine ulcerations in the inner mucosal lining of the large intestine that do not penetrate the bowel muscle wall. The Phase 2b trial is a placebo-controlled study that will enroll up to 28 patients to compare FW-UP, administered as an enema twice daily at a dose of 450 mg, to placebo enemas twice daily. Patient screening is underway at clinical trial sites in Italy and will start soon in Austria and Germany. The Phase 2b trial builds on preliminary data from a previous Phase 1a/2a trial evaluating a low-dose and high-dose of FW-UP in patients with UP and UPS. Data from the first 17 patients treated in the low-dose cohort demonstrated niclosamide to be well tolerated, with a durable therapeutic effect and a clinical remission rate of 59%. Although from early stage data, this rate of remission compares favorably to the rates of 38% to 44% reported for the commonly used steroid, budesonide. In data collected from the first four patients in the high-dose cohort, niclosamide was also shown to be well tolerated.

08:18 EDT Splash Beverage Group launches Copa di Vino 4-pack nationwide - Splash Beverage Group announced the launch of the all-new Copa di Vino 4-pack in celebration of Copa's 10th anniversary of providing premium wines by the glass, a customer favorite nationwide. Copa's 4-pack offers a new spin on customers' favorite premium wine by the glass that provides a fresh and clean look. Copa's new 4-pack presents enhanced merchandising at retail, delivering unity and a more prominent billboard on the shelf. The new packaging features a custom cutout in the classic Copa cup design that reveals the proprietary single cup inside. With Copa's new rollout, Splash Beverage Group has commenced shipping the new 4-packs to distributors nationwide. The product will retail for approximately $11.99, with occasional promotional pricing as low as $9.99. The Copa 4-pack will facilitate more penetration within the grocery and mass-market channels for the Copa di Vino brand franchise.

08:17 EDT Sonoma Pharmaceuticals up 70% at $9.15 after launching it products on Amazons

08:15 EDT Verizon, Yealink introduce 4G/LTE cellular desk phone - Verizon Business and Yealink announced the One Talk T67LTE wireless desk phone, the first advanced desk phone with embedded 4G/LTE cellular technology available in the United States. Available only with Verizon's One Talk service, the premier T67LTE was designed to support the hybrid worker, providing next generation workplace mobility, wireless freedom and peace of mind. Unlike today's existing VoIP phones that utilize a customer's internet connection, with the One Talk T67LTE, users will be able to enjoy a wireless and reliable experience, similar to a smartphone, in a feature-rich desk phone with a large 7-inch color touch screen. Leveraging Verizon's 4G Data network, the T67LTE frees up internet bandwidth which may help improve performance of other devices and apps on the customer's network.

08:14 EDT ManTech names David Hathaway as EVP, general manager of defense sector - ManTech (MANT) announced that it has named David Hathaway as Executive Vice President and General Manager of the company's Defense Sector. Reporting to Chief Operating Officer Matt Tait, Hathaway will lead strategic and operational initiatives delivering innovative technology solutions that support the critical missions of the company's Department of Defense customers. Hathaway succeeds Andrew Twomey who has led ManTech's Defense Sector since January 2015. Twomey is taking on a new strategic role within ManTech. Hathaway joins ManTech following a 25-year tenure at IBM (IBM) in Public Sector executive leadership where he was charged with the development and delivery of advanced solutions for military and intelligence customers.

08:13 EDT Ideanomics subsidiary to participate in DOE's electrified powertrain project - Wireless Advanced Vehicle Electrification, or WAVE, a subsidiary of Ideanomics announced its participation in a U.S. Department of Energy, or DOE, electrified powertrain project to develop the 1-megawatt wireless charging system for Class 8 electric trucks. The primary recipient of the cooperative agreement is Kenworth, who will collaborate with WAVE and Utah State University on system design. The project calls for WAVE systems at each end of a 400-mile regional haul route between Portland, OR, and Seattle, WA. Each charging station will deliver 1-megawatt of power from roadway-embedded charging pads, stationed at designated facilities in Seattle and Portland, to a specially equipped Kenworth T680 next-generation battery EV, enabling the vehicle to exceed its standard 150-mile range and complete the 400-mile route. At 1-megawatt, the system aims to charge the T680 batteries in 30 minutes or less. By comparison, a 250kW charger would take over 1.5 hours.

08:12 EDT Lightbridge expands board with appointment of two independent directors - Lightbridge (LTBR) announced that it has expanded its Board of Directors with the appointment of Sweta Chakraborty and Mark Tobin as independent directors, effective immediately. Chakraborty will serve as Chair of the newly constituted Environmental Social & Governance Committee, while Tobin will serve as Chair of the Compensation Committee. Chakraborty is a risk and behavioral scientist and expert on risks ranging from climate change to COVID-19. She has spent the last 12 years advising government agencies on science and technology policy. Tobin is a global finance and strategy executive with over 24 years of experience in international investment banking and public company leadership. Tobin serves as Chief Financial Officer at infrastructure services provider National Underground Group and serves on the Board of data storage solutions provider Qualstar Corporation (QBAK).

08:12 EDT Aspen Group director Douglas Kass buys 15.8K shares of common stock - In a regulatory filing, Aspen Group disclosed that board member Douglas Kass bought another 15.8K shares of common stock on September 24th in a total transaction size of $82.8K, boosting his stake by about 19%. Shares of Aspen Group are up 3.5% at $5.62 per share in pre-market trading.

08:11 EDT Lincoln Educational strengthens balance sheet through planned real estate deals - Lincoln Educational Services Corporation has entered into a sale-leaseback agreement for its Denver, CO and Grand Prairie, TX campuses. In addition, Lincoln has entered into a separate agreement to sell the property hosting its Nashville, TN campus as a precursor to a planned relocation in 2022 or 2023 to a more efficient and technologically advanced campus. In the aggregate, the two transactions are expected to generate gross proceeds of $81 million and significantly bolster the Company's balance sheet by providing it with the financial resources to execute on its long-term growth initiatives. The sale agreement for Lincoln's properties in Denver, CO and Grand Prairie, TX is for an aggregate purchase price of $46.5 million. Simultaneously with the closing of the sale, Lincoln and the purchaser will enter into a triple-net lease agreement pursuant to which the properties will be leased back to Lincoln for a twenty-year term with four subsequent five-year renewal options. Upon the closing of the sale, which is expected to occur in the fourth quarter of 2021, the Company anticipates recording a gain on sale of approximately $22 million. The sale-leaseback transaction will result in straight-line rent expense of approximately $3 million annually which is expected to be partially offset by a $1.5 million reduction in depreciation expense and interest savings of $0.8 million from the repayment of amounts owed to the Company's lender. Lincoln has also entered into a contract to sell its property in Nashville, TN for a purchase price of $34.5 million. Upon closing of the sale, which is expected to occur during the first quarter of 2022, the Company anticipates recording a gain on sale of approximately $29 million. Pursuant to the terms of the agreement, Lincoln is permitted to continue operating its Nashville campus on a rent free basis for a period of 12 months with an option to extend the rental period at negotiated rates. The Company plans to operate the existing Nashville campus until the relocation to the new campus is complete. While the new campus location has not yet been determined, the Company anticipates that the new facility will be EBITDA neutral given the anticipated efficiencies. The agreements for both of these real estate transactions contain various closing conditions so there can be no assurance that the conditions will be satisfied or waived and that the sales ultimately will be consummated on a timely basis or at all. Lincoln anticipates that the consummation of these real estate transactions will generate net proceeds of nearly $80 million, of which approximately $17 million will be used to repay the Company's outstanding term loan balance, resulting in interest savings of approximately $0.8 million. The Company also expects to invest $10 to $15 million for the buildout of its new Nashville campus with the remaining proceeds available for strategic growth initiatives including expansion of program offerings and new geographic markets as well as general working capital purposes. The Company plans to utilize its available Federal and State net operating losses to substantially offset the tax liability associated with the transactions.

08:10 EDT Kratos Defense receives $3.2M contract award for Next Generation small engine - Kratos Defense & Security Solutions announced that its Kratos Turbine Technologies, or KTT, Business has recently received an approximate $3.2M contract award for the development of a Next Generation small engine for a National Security Program. KTT is currently under contract and in development for several Next Generation turbojet, turbofan, and other engines for certain National Security priority areas, including unmanned aerial drone systems, cruise missiles, powered munitions and other platforms and systems. Work under this recent contract award will be performed at a secure Kratos technical, engineering and development facility. Due to customer, competitive and other considerations, no additional information is being provided related to this recent contract award. Stacey Rock, President of KTT, said, "At Kratos, affordability is a technology, and KTT is focused on disrupting the small turbojet and turbofan class market area with a family of new, high performance, high power, affordable engines which address our customers' rapidly expanding requirements. We believe that Kratos' digital engineering capabilities, which utilize an integrated digital approach with authoritative sources of system data and models across our entire organization's functions and disciplines is a competitive differentiator for our Company and significant value contributor for our customers."

08:09 EDT NovaBay to acquire DERMAdoctor for $15M - NovaBay announced it has entered into a definitive agreement to acquire DERMAdoctor, a privately-held company that commercializes dermatologist-developed skincare products, including all of its inventory, products and intellectual property, for a purchase price of $15M, comprised of $12M in cash at closing and up to an additional $3M in earnout payments contingent upon the DERMAdoctor business achieving predetermined financial targets for the 2022 and the 2023 fiscal years. DERMAdoctor produces and sells more than 30 products. DERMAdoctor sells its products through major retailers as well as its own website. The parties are targeting a closing of the transaction in Q4, subject to customary closing conditions.

08:09 EDT SME enrolls in DTE Energy's MIGreenPower program - DTE Energy announced SME's enrollment in DTE's MIGreenPower program. MIGreenPower is one of the largest voluntary renewable energy programs in the United States. Through the program, SME will attribute 100% of the electricity use at its Plymouth, Shelby Township and Livonia locations to DTE's wind and solar parks. Their clean energy commitment will reduce carbon dioxide emissions by 430 tons, which is equivalent to the greenhouse gas emissions from driving a passenger car nearly one million miles.

08:08 EDT Alignment Healthcare adds Abrazo Health, Carondelet Hospitals to its network - Medicare Advantage company Alignment Healthcare announced the addition of Abrazo Health, a Phoenix-based network of hospitals, emergency centers and physician practices, and Tucson-based Carondelet Health Network hospitals, emergency centers and physician practices, to its network starting Jan. 1, 2022. This agreement will expand access to care for Medicare-eligible beneficiaries in Arizona's Maricopa and Pima counties, where Alignment is launching Medicare Advantage plan options in 2022. "With two of the fastest-growing cities in the nation being in Maricopa County and large senior populations both in Maricopa and Pima, there is a demand for high-quality, coordinated care that better serves this vulnerable population," said John Kao, founder and CEO, Alignment Healthcare. "By partnering with top local providers in Arizona, we further deliver on our mission to provide access to the highest level of care for seniors in 2022 and beyond." In October, nearly 1M Medicare-eligible seniors in Pima and Maricopa Counties will be able to choose from Alignment's HMO and PPO plans during Medicare's annual enrollment period from Oct. 15 through Dec. 7 for coverage beginning Jan. 1, 2022.

08:07 EDT VinFast selects Cerence to power intelligent voice assistant - Cerence announced that VinFast has selected Cerence to power conversational AI across its lineup of smart EVs as it expands globally. VinFast is a member of Vingroup. Leveraging embedded and cloud-based technologies from Cerence, VinFast's AI-powered voice assistant, summoned with a simple "Hey VinFast," is an intelligent, trusted companion deeply integrated with the car. Cerence provides VinFast drivers with conversational AI-enabled access to everything from navigation and traffic to phone calling and messaging to media, weather, news, tourist attractions, etc. Drivers can even control key vehicle functions like climate control and advanced driver-assistance systems with their voice and access important car status information like tire pressure or warning lights.

08:06 EDT Capital Senior Living postpones upcoming Special Meeting of stockholders - Capital Senior Living Corporation announced that it is postponing its upcoming Special Meeting of Stockholders to October 22.

08:05 EDT I-Mab announces approval of phase 2 trial for enoblituzumab in China - I-Mab (IMAB) announced that the Center for Drug Evaluation, or CDE, of China National Medical Products Administration, or NMPA, has accepted the Company's IND application to initiate a phase 2 trial for enoblituzumab in combination with pembrolizumab, Keytruda, in patients with selected solid tumors in China. I-Mab has in-licensed the rights to exclusively develop and commercialize enoblituzumab in Greater China from MacroGenics (MGNX). Enoblituzumab is a highly differentiated humanized monoclonal antibody directed against B7-H3, a member of the B7 family of T-cell checkpoint regulators. B7-H3 plays a key role in regulating immune response against cancers and is widely expressed in multiple cancers. Its presence on tumors is associated with poor clinical prognosis.

08:04 EDT Reservoir Media supports agreement between NMPA, Roblox - Reservoir Media (RSVR) supported the new agreement between the National Music Publishers' Association and video gaming platform Roblox (RBLX). The agreement includes a settlement for previous claims, and also sets the foundation for future creative and commercial partnerships, plus opt-in go-forward licenses with publishers, per the official announcement. With over 48 million daily active users, Roblox drives new revenue streams through virtual launch parties and concerts, music in games, persistent music worlds, and virtual merchandise. Golnar Khosrowshahi, Reservoir's Founder and CEO, who is also an NMPA Board Director said, "It is another proud day for the publishing and songwriting community, as we celebrate this new agreement with Roblox. We look forward to coming to the table with Roblox and building creative and engaging experiences on the platform that benefit music rights holders and Roblox users alike."

08:03 EDT Iterum Therapeutics expects cash to fund operations into 2H23 - Iterum notes that cash, cash equivalents and short-term investments were $91.5 million at the end of the second quarter of 2021. Based on the current operating plan and subject to final determination of the design and planned conduct of additional clinical and potential nonclinical development for sulopenem, the Company believes that it is well positioned financially to fund its operations into the second half of 2023.

08:03 EDT Iterum Therapeutics evaluating design for additional Phase 3 uUTI study - Iterum Therapeutics announced that the Company held a Type A meeting with the U.S. Food and Drug Administration during the third quarter of 2021 to discuss the steps required for potential resubmission of the New Drug Application for sulopenem etzadroxil/probenecid for the treatment of uncomplicated urinary tract infections. In July, the Company announced that it had received a Complete Response Letter from the FDA requesting additional data to support approval of oral sulopenem for the treatment of adult women with a uUTI. "We had a successful meeting with the FDA and have established various potential paths forward to address the request in the CRL for additional data in support of our NDA," said Corey Fishman, Chief Executive Officer. "We are currently evaluating the optimal design for an additional Phase 3 uUTI study to be conducted prior to the potential resubmission of the NDA. We continue to believe in the ability of sulopenem to treat the growing problem of multi-drug resistant UTIs in the community."

08:02 EDT Motus GI Holdings announces passing of director Sam Nussbaum - Motus GI Holdings announced with profound sadness that Samuel Nussbaum, MD, an independent director on the Company's board of directors, passed away on September 23, 2021. Dr. Nussbaum had proudly served on the Company's board of directors since 2016, where he was a member of the compensation, and nominating and corporate governance committees.

07:47 EDT Jacobs wins seven awards on GSA ASTRO contract - Jacobs has won seven awards on the General Services Administration's, or GSA, ASTRO contract. The multiple-award, indefinite delivery/indefinite quantity, or IDIQ, contract has no defined ceiling value but is anticipated to have a multi-billion-dollar budget over its potential 10-year ordering period. Sponsored by the Department of Defense, or DoD, the ASTRO program will be managed by GSA's Federal Systems Integration and Management Center, or FEDSIM. The program focuses on providing the DoD innovative, future technology, products, solutions and capabilities across all domains as the Department operationalizes convergence. ASTRO's scope includes the full lifecycle of development, integration, operation and maintenance for manned, unmanned and optionally-manned systems, robotics, sensors, vehicles and platforms. The scope also covers the services that support those systems as well as the analysis and visualization of data they collect.

07:44 EDT CloudMD nominates Duncan Hannay, Karen Adams to board of directors - CloudMD Software is excited to announce that the company will be nominating two new business leaders to its Board of Directors for the 2021 annual general meeting of shareholders scheduled for November 9th, 2021. The new Board of Directors will consist of five directors, including two new nominees for election. The new nominees for the Board of Directors are: Duncan Hannay. Hannay is currently the Chief Executive Officer of the Ontario Lottery and Gaming Corporation and brings more than 25 years of experience growing businesses across industries, channels and locations around the world. Karen Adams. Ms. Adams is currently President of CloudMD as well as its Global Head, Enterprise Health Solutions. The three incumbent directors for re-election are Mark Kohler, Christopher Cherry and Essam Hamza. The Company also announces that is has appointed KPMG LLP, Chartered Professional Accountants as the Company's independent auditors to hold office until the end of the next annual general meeting of shareholders. Effective September 9th, 2021, at the request of the Company, CloudMD's predecessor auditors, Harbourside LLP, Chartered Professional Accountant, resigned as auditors and KPMG was appointed to fill their vacancy for the fiscal year ended December 31, 2021. The Company has granted stock options and restricted share units in the ordinary course to certain directors and officers, under its Stock Option Plan and RSU Plan to purchase an aggregate of 1,250,000 common shares of the Company. The exercise price of the stock options granted was set at $1.75 per share. The stock options and restricted share units are subject to the terms of the Company's Stock Option Plan and RSU Plan and any necessary regulatory approvals.

07:41 EDT Dicerna doses 1st subjects with investigational GalXC RNAi therapeutic for AUD - Dicerna Pharmaceuticals announced that it dosed the first subjects in its Phase 1 clinical trial to assess DCR-AUD, Dicerna's investigational GalXC RNAi therapeutic in development for the treatment of alcohol use disorder. The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of DCR-AUD in healthy volunteers. The trial will also assess the interaction between DCR-AUD administration and alcohol consumption using standardized Ethanol Interaction Assessments performed serially over the trial's duration. AUD is characterized by the inability to stop or control alcohol use despite social, occupational or health consequences.1 Treatment approaches include psychosocial support and pharmacotherapy, but many individuals with AUD do not receive treatment, and currently available pharmacotherapies are not widely prescribed.2 Overall, of the estimated 14M individuals in the U.S. with AUD, fewer than 1.4 million receive treatment of any kind.3,4 "We designed DCR-AUD leveraging our GalXC RNAi technology to serve as a potential therapeutic that offers real-time physiological feedback to complement the evidence-based psychosocial treatments used to help individuals with AUD," said Shreeram Aradhye, M.D., Executive Vice President and Chief Medical Officer at Dicerna. "We are pleased to initiate clinical development of DCR-AUD and look forward to sharing interim data later next year." The randomized, double-blind Phase 1 clinical trial will evaluate single doses of DCR-AUD compared to placebo in up to 36 healthy volunteers over a 24-week observation period.

07:38 EDT Cytokinetics' annual Communications Fellowship Grant program calls for proposals - Cytokinetics, Incorporated announced a call for proposals for the fourth annual Cytokinetics Communications Fellowship Grant program. The program awards five grants worth $20,000 each to patient advocacy organizations serving the amyotrophic lateral sclerosis, heart failure, hypertrophic cardiomyopathy, or spinal muscular atrophy communities, and is intended to support increased capacity in communications and outreach.

07:36 EDT Lizhi's says Audio Engineering Technology Research Center accredited - LIZHI announced that its Audio Engineering Technology Research Center of Guangdong Province in China has been recognized by the Guangdong Science and Technology Department on its 2021 list of Engineering Technology Research Centers of Guangdong Province. The certificate recognizing the research center's accreditation was officially unveiled today.

07:35 EDT Crown Electrokinetics signs its first commercial customer, MetroSpaces - Crown Electrokinetics has signed its first commercial customer, MetroSpaces, a proptech company combining world-class real estate development with cutting-edge technology. Crown will install its Smart Window Inserts in MetroSpaces' 70,000 square-foot Houston, Texas office building. Crown's Smart Window Inserts aims to enhance the efficiency of existing windows, eliminating the need to replace the glass by easily fitting into window frames. It also acts as an additional pane of glass, further insulating the building from outside temperatures. And, powered by solar, Smart Window Insert will ultimately be able to function without wiring into the building. Initial field test results suggest that the inserts can reduce energy costs of office buildings by approximately 26%. Crown expects to start installation of the Smart Window Inserts during the Q1 of 2022.

07:33 EDT Assurant announces COO Mergelmeyer to retire, Keith Meier to succeed - Assurant announced that Gene Mergelmeyer, chief operating officer, with 34 years of tenure with the company, plans to retire at the end of 2021. As a result, president and incoming CEO Keith Demmings is announcing leadership appointments to support its go-forward business strategy. The appointments, all of which will be effective January 1. are focused on advancing Assurant's business strategy and market leadership in the connected world with a focus on delivering superior customer experiences. Keith Meier, president, Assurant International will succeed Mergelmeyer as COO. Federico Bunge, president of Assurant's Latin America operations will succeed Meier to lead International and will report to Biju Nair, EVP and recently named president, Global Connected Living.

07:32 EDT Arrowhead earns $10M milestone payment from Janssen Pharmaceuticals - Arrowhead (ARWR) announced that it earned a $10M milestone payment from Janssen Pharmaceuticals (JNJ). The milestone payment was earned after Janssen dosed the fifth patient in a Phase 1 clinical study of ARO-JNJ1, an investigational RNAi therapeutic candidate which utilizes Arrowhead's proprietary Targeted RNAi Molecule platform. Arrowhead entered into a license and collaboration agreement, and into a research collaboration and option agreement, with Janssen in October 2018. Arrowhead is eligible for additional payments when future milestones are met and is also eligible for royalties on commercial sales of ARO-JNJ1.

07:32 EDT nCino appoints Anthony Morris as SVP, global banking strategy, customer advisory - nCino, Inc. (NCNO) announced the appointment of Anthony Morris as SVP of Global Banking Strategy & Customer Advisory. As the Vice President and Global Head of Banking Go-to-Market at Salesforce (CRM) for the past decade, Morris advised hundreds of bank customers on how to best leverage the cloud to deliver their digital transformation strategies across a variety of business lines, segments, and programs. In his new role at nCino, Morris will engage with nCino's global bank customers and prospects to drive their adoption of the nCino Bank Operating System and help refine go-to-market strategies to continue expanding the nCino ecosystem.

07:18 EDT Laix receives not in compliance letter from NYSE - LAIX announced that it has received a letter from the NYSE dated September 17 notifying the Company that it is below compliance standards due to the trading price of the Company's American depositary shares and the applicable cure period for the Company to regain compliance expires on March 17, 2022. Once notified, the company must bring its ADS trading price and average ADS trading price back above $1.00 within the applicable cure period following receipt of the notification. To address this issue, LAIX intends to monitor the market conditions of its listed securities and is still considering its options.

07:16 EDT Ero Copper announces results of optimized feasability study for Boa Esperanca - Ero Copper is pleased to announce the results of its optimized Feasibility Study on the Boa Esperanca Copper Project, located in Para State, Brazil. HIGHLIGHTS: 41.8% after-tax internal rate of return and $380 million after-tax net present value based on Consensus Copper Price and 5.00 BRL:USD exchange rate; Doubled life-of-mine copper production to approximately 326,000 tonnes from 163,000 tonnes in the 2017 Study with increased mine life of twelve years; Increased annual average LOM copper production from approximately 18,000 tonnes to over 27,000 tonnes, with the first five years of production averaging approximately 35,000 tonnes per annum. Mine life of twelve years supported by updated proven mineral reserves of 30.7 million tonnes at 0.89% copper and probable mineral reserves of 12.4 million tonnes at 0.67% copper, containing a total of 356.6 thousand tonnes of copper, a 93% increase in contained copper as compared to the 2017 Study; Low capital-intensity of approximately $8,400 per tonne of copper produced annually over the first 5 years of the Project resulting in rapid payback of 1.4 years at Consensus Copper Price; Significant exploration upside identified within an under-explored area within the final pit limits, known as the "Gap Zone", expected to enhance the Project by confirming continuity of mineralization between near-surface high-grade zones and high-grade zones near the pit limits at depth; and, converting material currently classified as waste into mineral resources. Subsequent to August 31, 2021, or the effective date of the mineral resource and mineral reserve estimates in the 2021 Feasibility Study, ten exploration holes were drilled in the Gap Zone, all of which showed mineralization. To date, assay results have been received for three of these holes. Results are highlighted by hole BSPD-166 that intercepted 21.2 meters grading 0.98% copper and 15.3 meters grading 1.25% copper and BSPD-169 that intercepted 64.9 meters grade 0.86% copper including 15.0 meters grading 1.40% copper; and Detailed engineering design efforts are currently underway with early construction works expected to commence during H1 2022, subject to the approval of Ero's Board of Directors.

07:13 EDT Salarius Pharmaceuticals receives $2.7M in payment from CPRIT - Salarius Pharmaceuticals announced the receipt of a $2.7M payment under its existing contract with the Cancer Prevention and Research Institute of Texas, or CPRIT. The payment is part of a non-dilutive grant that was originally awarded in 2016 to support Salarius' operations and development of its lead drug candidate, seclidemstat. Seclidemstat s a novel, oral tablet, reversible inhibitor of lysine-specific histone demethylase 1, an enzyme that plays a key role in the development and progression of several cancers. This latest disbursement of CPRIT funds is additive to the $33M in cash Salarius previously reported on its balance sheet as of June 30, 2021, and up to $2.1M in funding remains available to Salarius under the original 2016 CPRIT Award. "The non-dilutive financial support Salarius has received from CPRIT during the past five years continues to play an instrumental role in our success in advancing the development of seclidemstat," stated David Arthur, CEO of Salarius. "Since the original CPRIT grant, Salarius has initiated research partnerships, fortified its intellectual property portfolio and expanded the exploration of seclidemstat into new cancer indications. In all, patients are being actively recruited for clinical trials across five patient groups, three in high unmet need sarcomas and two in high unmet need hematologic cancers."

07:12 EDT Procept BioRobotics announces Cigna adds Aquablation therapy to coverage policy - PROCEPT BioRobotics (PRCT) announced a new positive coverage decision from Cigna (CI), expanding access to Aquablation therapy for the treatment of their members with Benign Prostatic Hyperplasia. The revised policy is effective September 15, 2021. "We are pleased with Cigna's decision to cover Aquablation therapy for the treatment of lower urinary tract symptoms due to BPH. This coverage update will provide access to an effective, safe and durable treatment option to millions of members nationwide," said Reza Zadno, President and CEO of Procept BioRobotics. "Payors continue to rely on high quality clinical data when establishing coverage criteria for new treatments, Aquablation therapy is the only BPH surgical treatment with proven clinical outcomes, independent of the size or the shape of the prostate, and a reduced risk of sexual side effects. With this updated policy, Cigna joins Medicare and numerous private health plans that cover Aquablation therapy."

07:11 EDT DoubleDown announces launch of Undead World: Hero Survival - DoubleDown Interactive announced the worldwide launch of its first-ever RPG, Undead World: Hero Survival, a zombie apocalypse game that features hero-collecting and idle gameplay. The game launched on September 27, 2021 and marks a departure from the social casino genre for the company.

07:08 EDT Cloopen announces $40M share repurchase program - Cloopen Group announced that its board of directors has authorized a share repurchase program under which the company may repurchase up to $40M of its Class A ordinary shares in the form of American depositary shares during a twelve-month period commencing on September 28.

07:07 EDT Altimmune announces results from 12-week Phase 1 trial of ALT-801 - Altimmune announced positive results from a 12-week, Phase 1 trial of pemvidutide, an investigational glucagon-like peptide-1/glucagon dual receptor agonist. The Phase 1 study was a first-in-human, randomized, placebo-controlled, single ascending dose and multiple ascending dose study in overweight and obese volunteers performed in Australia under a clinical trial application. Eligible participants included healthy, non-diabetic subjects with a minimum body mass index of 25 kg/m2. Thirty-four subjects in the MAD portion of the study were assigned to receive one of three subcutaneous doses of pemvidutide or placebo once weekly for 12 weeks without dose titration. Behavioral and caloric restrictive interventions were not employed. At 12 weeks, subjects receiving pemvidutide achieved mean weight losses of 4.9%, 10.3%, and 9.0% at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, with the placebo group experiencing a mean weight loss of 1.6%. Weight loss occurred rapidly and consistently over 12-weeks. Side effects were mild to moderate, with no serious or severe treatment-emergent adverse events. Importantly, no discontinuations due to adverse events were reported The 1.8 mg dose cohort experienced the highest weight loss, with 100% of subjects losing at least 5% of body weight and 55% of subjects losing at least 10% of their body weight. The amounts of weight loss at the 1.8 and 2.4 mg doses were essentially the same given the sample size and overlapping confidence intervals. No correlation was found between the magnitude of weight loss and either age or baseline BMI. Favorable trends were observed in secondary measures, including reductions in systolic and diastolic blood pressure, serum lipids, and HOMA-IR. In addition, a rise in ketone bodies was observed, consistent with the effects of glucagon on fat metabolism. Even without dose titration, the symptoms experienced by subjects who received pemvidutide 1.8 mg were predominantly mild, did not need treatment and were consistent with known effects of GLP-1 therapies. Further, tolerability decreased with higher dose levels. There were no hyperglycemia adverse events and no increases in the mean heart rate were observed at 6 and 12 weeks of therapy. One patient experienced elevated ALT levels that resolved rapidly after a pause in dosing. An Investigational New Drug application in non-alcoholic steatohepatitis has cleared the U.S. Food and Drug Administration review and will enable additional clinical studies beyond the current Phase 1 trial, including a 12-week trial to measure reduction in liver fat content in diabetic and non-diabetic subjects with non-alcoholic fatty liver disease, which is expected to commence in the near future. The Company has commenced a drug-drug interaction trial and also plans to conduct a trial of glucose control in patients with type 2 diabetes that is anticipated to start in the fourth quarter of this year. Altimmune also intends to begin a 52-week Phase 2 biopsy-driven NASH trial in H1 2022. The Company intends to file a second IND application in obesity in Q4 2021 with plans to initiate a 48-week, Phase 2 obesity trial in H1 2022.

07:07 EDT Village Farms enters option agreement to acquire 80% of Leli Holland - Village Farms announced it has entered into an option agreement whereby the company has received the irrevocable right to acquire an 80% ownership interest in Netherlands-based Leli Holland B.V. upon payment of EUR50,000. Leli is one of the ten applicants selected by lottery to receive a license to legally cultivate and distribute cannabis to retailers when the Dutch government implements its Experiment to Investigate Closed Cannabis Supply Chains. The Dutch Supply Chain Experiment, which is scheduled to operate for a minimum of four years with the potential for national expansions, is expected to be the first legal recreational cannabis market in Europe. The Option Agreement provides for Village Farms to acquire 80% of Leli's shares for a total of EUR3,950,000 million, of which EUR950,000 is due and payable to Leli's shareholders upon the exercise of the Option and the remainder due and payable in three installments subject to achievement of certain project development milestones. The option is exercisable at the sole discretion of Village Farms.

07:04 EDT TransAlta to suspend Sundance Unit 5 repowering project - Following an in-depth evaluation and assessment of the Sundance Unit 5 repowering project, the company has determined to suspend the project. This decision was made due to escalating costs, changing supply and demand dynamics and forecasted power prices in the Alberta market, as well as risks associated with the evolving regulatory environment. The company expects to redeploy the capital previously allocated to the Sundance Unit 5 repowering to renewable growth projects. In addition, the company has determined to retire Keephills Unit 1 effective December 31 and to retire Sundance Unit 4 effective April 1, 2022, and has provided notice to the Alberta Electric System Operator of its intention to retire such units. The retirement decisions were largely driven by TransAlta's assessment of future market conditions and the age and condition of the units.

07:03 EDT XPO Logistics appoints Christine Robinne as head of technology for Europe - XPO Logistics (XPO) has announced the appointment of Christine Robinne to lead the company's technology organization and digital strategy in Europe. She will report to Luis Gomez, president - Europe, and to Mario Harik, XPO's chief information officer. Robinne joins XPO from Heineken International (HEINY), where she most recently led the digitalization of Heineken's operations in Europe as director of transformation and technology.

06:55 EDT PSEG initiates long-term earnings growth rate forecast of 5%-7%

06:54 EDT Vale reports employees are returning to surface in Totten Mine - Vale informs that the return of employees to surface at the Company's Totten Mine in Sudbury, Ontario continues this morning following the successful ascent of several individuals overnight. On Sunday, 39 employees were unable to exit the mine due to damage in the shaft that houses the conveyance used to transport employees between surface and underground. While conditions in the shaft were evaluated, employees reported to underground refuge stations as part of the company's standard procedures. Sunday evening, employees started making their way to surface via a secondary egress ladderway system. Nineteen employees returned to surface early this morning and the remainder are on their way. The remaining employees are expected to be on surface later this morning. The employees that have returned to surface are in good health and eager to return home. The employees' exit is being supported by Vale's mine rescue team and Ontario Mine Rescue.

06:52 EDT Velodyne Lidar selected by HIMaC to improve traffic and energy efficiency - Velodyne Lidar announced its Intelligent Infrastructure Solution has been selected by the HORIBA Institute for Mobility and Connectivity, or HIMaC, in the University of California, Irvine, or UCI, Samueli School of Engineering. HIMaC plans to equip 25 intersections at UCI and the adjacent City of Irvine with Velodyne's lidar-based Intelligent Infrastructure Solution as part of a major study on improving traffic and energy efficiency, road safety and air quality. The Intelligent Infrastructure Solution deployment is supported by a $6M grant recently awarded to HIMaC by the Vehicle Technology Office of the U.S. Department of Energy, or DOE. HIMaC will create a Public Road Network Platform for the development, evaluation and deployment of emerging and future connected and autonomous vehicle, or CAV, technologies. The Intelligent Infrastructure Solution combines Velodyne's award-winning lidar sensors with powerful AI software to monitor traffic networks and public spaces.

06:47 EDT TopBuild to appoint Robert Kuhns as CFO after John Peterson's retirement - TopBuild announced that after a more than 42-year career in finance and over six years with TopBuild, John Peterson, will be retiring from his position as Vice President and CFO of the Company effective March 31, 2022. At that time, Robert Kuhns, Vice President and Corporate Controller, will assume the CFO position. Kuhns joined TopBuild in July 2018 as Vice President, Controller. Prior to joining TopBuild, he worked at Mohawk Industries for eleven years in a number of roles including Senior Director/Assistant Controller, Senior Director of International Finance and Division Controller. Prior to joining Mohawk, Rob was with NCH Corporation where he served as Director of International Treasury and as a Division Controller. He began his career in the accounting department of Ingersoll-Rand Company.

06:44 EDT Agnico Eagle, Kirkland Lake Gold to combine in merger of equals - Agnico Eagle (AEM) and Kirkland Lake Gold (KL) announced that they have entered into an agreement to combine in a merger of equals, with the combined company to continue under the name Agnico Eagle Mines. Upon closing of the Merger, the company is expected to have $2.3B of available liquidity, a mineral reserve base of 48M ounces of gold, which has doubled over the last 10 years, and a pipeline of development and exploration projects to drive sustainable, low-risk growth. Under the merger agreement, which the board of Directors of both companies have unanimously approved, the new Agnico Eagle will be led by a combined board and management team. The transaction is expected to close in December or in Q1 of 2022. After consultation with its outside financial and legal advisors, the board of Agnico Eagle has unanimously approved the merger agreement. The board of Agnico Eagle recommends that Agnico Eagle shareholders vote in favor of the merger. The merger will be effected by way of a plan of arrangement of Kirkland Lake Gold under the Business Corporations Act. At closing, all Kirkland Lake Gold common shares will be exchanged for the consideration, being 0.7935 of an Agnico Eagle common share, for each Kirkland Lake Gold common share held. The arrangement will require the approval of at least 66 2/3% of the votes cast by the shareholders of Kirkland Lake Gold voting at a special meeting of Kirkland Lake Gold's shareholders. The issuance of shares by Agnico Eagle under the merger is subject to the approval of a simple majority of votes cast by Agnico Eagle shareholders at a special meeting of Agnico Eagle's shareholders. The merger is also subject to closing conditions customary in transactions of this nature, including receipt of Competition Act and Foreign Acquisitions and Takeovers Act 1975 clearance, Ontario court approval and applicable stock exchange approvals. The merger agreement includes reciprocal non-solicitation provisions, a reciprocal $450M termination fee and a $20M expense reimbursement payable in certain circumstances. Officers and directors of Agnico Eagle have entered into support and voting agreements with Kirkland Lake Gold, agreeing to vote their shares in favor of the merger. Officers and directors of Kirkland Lake Gold have entered into support and voting agreements with Agnico Eagle, agreeing to vote their shares in favor of the merger. Agnico Eagle and Kirkland Lake Gold have agreed to use their commercially reasonable efforts to complete the merger on or before March 31, 2022. It is anticipated that both shareholder meetings will take place in Q4 and that closing will occur in December or in the first quarter of 2022 subject to satisfaction of the conditions under the merger agreement. Following completion of the merger, the shares of the new Agnico Eagle will continue to trade on the Toronto Stock Exchange and the New York Stock Exchange, subject to approval or acceptance of each exchange in respect of the Agnico Eagle shares being issued as part of the consideration. Kirkland Lake Gold's shares will be de-listed from the Toronto Stock Exchange, the New York Stock Exchange, and the Australian Securities Exchange following closing.

06:41 EDT FDA grants Priority Review to ViiV Healthcare's NDA for cabotegravir long-acting - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer (PFE) and Shionogi as shareholders, announced that the U.S. FDA has accepted and granted Priority Review for a New Drug Application for investigational, injectable cabotegravir long-acting for pre-exposure prophylaxis, or PrEP. The Priority Review designation of cabotegravir long-acting for PrEP builds upon its prior identification as a Breakthrough Therapy by the FDA. If approved, cabotegravir would be the first, long-acting therapy for the prevention of HIV for individuals at risk of sexually acquired HIV-1 infection, who have a negative HIV-1 test prior to initiation. The FDA has set a target approval date of 24 January 2022.

06:37 EDT Naked Brand Group chairman says found 'disruptive opportunity' in clean energy - In an update to shareholders released on Friday, Naked Brand Group chairman stated: "On August 20th at our Annual Meeting of Shareholders, I provided an update on the status of our plans to find a merger or acquisition partner following the divestiture of the bricks-and-mortar operations of Bendon that resulted in an expanded balance sheet with a net cash position of $270 million USD for Naked Brand Group. I am happy to report that after extensive searching and due diligence, we believe we have found a disruptive opportunity in the clean technology sector. Due diligence on both sides is progressing and we believe the business combination will reward our patient shareholders. During my career as an owner and operator of many diverse businesses, I have always been attracted to commercial opportunities that benefit our environment and help contribute to the growing ESG mandates that major corporations are implementing today across the globe. This company is a market leader with cutting edge patented proprietary technology that we believe satisfies those EGS mandates. We have made significant progress over the past few weeks and believe the path to a definitive agreement is in sight. However, there can be no assurance that we will sign a definitive agreement, or if we do sign an agreement, that we will be able to close the business combination." Shares of Naked Brand are up another 3.4% in pre-market trading at 86c per share after yesterday's 22% gain.

06:36 EDT Thor Industries says RVIA estimate of 577,200 wholesale shipments is reasonable - "While we expect these factors will continue to present challenges in fiscal 2022, our positive long-term outlook for the RV industry and THOR Industries remains unchanged. We believe the recent RVIA most-likely estimate of approximately 577,200 unit wholesale shipments in calendar 2021 and its forecast of a 4.0% increase in calendar 2022 wholesale shipments over calendar 2021 shipments are reasonable," said Martin.

06:33 EDT Agnico Eagle, Kirkland Lake Gold announce merger of equals - Agnico Eagle Mines (AEM) and Kirkland Lake Gold (KL) announced that they have entered into an agreement to combine in a merger of equals, with the combined company to continue under the name "Agnico Eagle Mines Limited". The Merger will establish the new Agnico Eagle as the gold industry's highest-quality senior producer, with the lowest unit costs, highest margins, most favourable risk profile and industry-leading best practices in key areas of environmental, social and governance. Upon closing of the Merger, the company is expected to have $2.3B of available liquidity, a mineral reserve base of 48M ounces of gold, which has doubled over the last 10 years, and an extensive pipeline of development and exploration projects to drive sustainable, low-risk growth. Under the Merger Agreement, which the Board of Directors of both companies have unanimously approved, the new Agnico Eagle will be led by a combined board and management team of experienced mining and business leaders, bringing together the proven cultures, strengths and capabilities of both companies. The transaction is expected to close in December 2021 or in the first quarter of 2022. Pursuant to the Merger Agreement, Kirkland Lake Gold shareholders will receive 0.7935 of an Agnico Eagle common share for each Kirkland Lake Gold common share held. The Consideration to Kirkland Lake Gold represents approximately a 1% premium to the 10-day volume weighted average prices on the Toronto Stock Exchange, as at close of trading Friday September 24, 2021 and implies a combined market capitalization of approximately $24B. Upon closing, existing Agnico Eagle and Kirkland Lake Gold shareholders will own approximately 54% and 46% of the combined company, respectively.

06:31 EDT Agnico Eagle, Kirkland Lake Gold announce merger of equals

06:24 EDT Sanofi sees first results from booster studies by end of Q4 - Sanofi (SNY) said in a statement that it continues its efforts in the fight against the COVID-19 pandemic with its adjuvanted recombinant protein candidate vaccine, developed in partnership with GSK (GSK). In parallel to its ongoing Phase 3 efficacy and safety study, Sanofi has expanded its development program to include a study of the vaccine as a potentially broadly protective booster to address evolving public health needs. Recently published preclinical data indicated the candidate has the potential to strongly boost immune responses following primary vaccination across multiple vaccine technology platforms and against a broad spectrum of variants of concern, Sanofi said. The booster studies began this summer in the U.S., Australia, France, and the UK. First results are expected by the end of Q4 2021.

06:19 EDT ViiV Healthcare announces exclusive license agreement with Shionogi for S-36559 - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer (PFE) and Shionogi as shareholders, announced an exclusive collaboration and license agreement with Shionogi & Co. Ltd. for S-365598, a third-generation investigational integrase strand transfer inhibitor with potential for use in ultra long-acting HIV regimens. Under the terms of the agreement, ViiV Healthcare will make an upfront payment of GBP20M to Shionogi, a GBP15M payment for the achievement of a clinical development milestone and royalties on net sales. The royalty levels are aligned with those in Shionogi's existing integrase inhibitor agreements with ViiV Healthcare. Shionogi will contribute to development costs up to an annual maximum.

06:04 EDT Ormat Technologies, PT Archi to establish joint venture - Ormat Technologies and PT Archi Indonesia, one of the largest pure-play gold mining companies in Indonesia and Southeast Asia, announced the signing of an agreement to establish a Joint Venture company, PT Toka Tindung Geothermal. This JV company is designed to explore the potential of geothermal energy prospects in the Bitung area of North Sulawesi region, especially within the Toka Tindung gold mine concession area. This is also in line with the Government's target to expand electricity generation from renewable energy sources. The shareholding composition of TTG, subject to completion of certain conditions, which fall under a Power Purchase Agreement, are 75% shareholding interest will be entitled to Ormat, while the rest of 25% shareholding interest will be owned by Archi. TTG aims to develop a geothermal power project within the Toka Tindung mining concessions on an exclusive basis. Ormat will execute the exploration drilling program at the Klabat Wineru prospect in the North Sulawesi province and ultimately the field development drilling program, design, engineering, procurement, financing, construction, testing, commissioning, ownership, management, operation and maintenance of the Geothermal Facilities.

06:01 EDT IHS Markit reports Q3 cash flow from operations of $421M, free cash flow $344M

05:48 EDT Liberty Oilfield Services achieves 24 hours of continuous pumping time - Liberty Oilfield Services announced that its team has collectively achieved the milestone of 24-hours of continuous plug and perf pumping time for Kaiser-Francis Oil Company in the Permian Basin. By delivering a full 1,440 minutes of pumping time with zero non-productive time, Liberty crews were able to attain the goal of Liberty's Operation 1440.

05:41 EDT Eisai initiates rolling submission to FDA of lecanemab BLA - BioArctic partner Eisai announced that they have initiated a rolling submission to the FDA of a biologics license application, or BLA, for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer's disease. The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early Alzheimer's disease and confirmed amyloid pathology. The lecanemab Phase 2b trial results demonstrated a high degree of Ass plaque lowering and consistent reduction of clinical decline across several clinical endpoints. The correlation between the extent of Ass plaque reduction and effect on clinical endpoints in the Phase 2b study further supports Ass as a surrogate endpoint that is reasonably likely to predict clinical benefit. Eisai is utilizing the accelerated approval pathway after discussions with the FDA and aims to bring a new potential treatment option to people living with early AD, their families and healthcare professionals.

05:37 EDT Huntsman, KPX chemical establish polyurethane system solutions joint venture - KPX Chemical and Huntsman announced the establishment of a joint venture named KPX Huntsman Polyurethanes Automotive, or KHPUA. The joint venture will create and provide polyurethane system solutions to Korean automakers from a specialty polyurethanes manufacturing facility at KPX Chemical's Ulsan plant. Operations are expected to commence by the end of October. The Korean automotive industry is undergoing changes and presents new opportunities for polyurethane system solutions.